Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. has enrolled the 25th participant in a pioneering clinical trial for MB22001, its take-home microdosing treatment for Major Depressive Disorder, showing promise with earlier trial phases indicating significant mood, sleep, and symptom improvements. The company stands out as the first to conduct multiple Phase 2B trials with government and regulatory approvals for at-home use of microdosed lysergic acid diethylamide. Additionally, MindBio is preparing to expand its research to PMS and PMDD treatments, eyeing strategic investments for these upcoming trials.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
